4-isocyanato-1-methylpiperidine | 1236140-75-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-isocyanato-1-methylpiperidine
• CAS: 1236140-75-2
• 化学式: C₇H₁₂N₂O
• 分子量: 140.185
• InChiKey: FHCYSJYLWYPKLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-isocyanato-1-methylpiperidine 、 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Radiosynthesis and Evaluation of [¹¹C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography

  摘要：

  Fatty acid amide hydrolase (FAAH) plays a key role in regulating the tone of the endocannabinoid system. Radiotracers are required to image and quantify FAAH activity in vivo. We have synthesized a series of potent FAAH inhibitors encompassing two classes of N-alkyl-O-arylcarbamates and radiolabeled eight of them with carbon-11. The [C-11-carbonyl]-radiotracers were evaluated in vitro and ex vivo in rats as potential FAAH imaging agents for positron emission tomography (PET). Both sets of [C-11] O-arylcarbamates showed good to excellent brain penetration and an appropriate regional distribution. Pretreatments with a FAAH inhibitor demonstrated that 80-95% of brain uptake of radioactivity constituted binding of the radiotracers to FAAH. Brain extraction measurements showed that binding to FAAH was irreversible and kinetically different for the two classes of carbamates. These promising results are discussed in terms of the requirements of a suitable radiotracer for the in vivo imaging of FAAH using PET.

  DOI：

  10.1021/jm301492y
• 作为产物：
  描述：

  4-氨基-1-甲基哌啶 、 三光气 在 三乙胺 作用下， 以 甲苯 为溶剂， 反应 4.5h， 生成 4-isocyanato-1-methylpiperidine
  参考文献：
  名称：

  (Z)-1-(3-((1H-Pyrrol-2-yl)methylene)-2-oxindolin-6-yl)-3-(isoxazol-3-yl)脲衍生物的发现作为新型和口服高效用于潜在结直肠癌免疫治疗的 CSF-1R 抑制剂

  摘要：

  通过阻断 CSF-1/CSF-1R 信号转导抑制肿瘤相关巨噬细胞的极化或存活已成为癌症免疫治疗的一种有前景的策略。在此，设计了一系列( Z )-1-(3-((1 H -pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)脲衍生物，合成并评估为用于结直肠癌免疫治疗的新型和口服高效 CSF-1R 抑制剂。在这些衍生物中，发现化合物21具有优异的 CSF-1R 抑制活性 (IC 50 = 2.1 nM) 和对结肠直肠癌细胞的有效抗增殖活性。化合物21通过抑制巨噬细胞的迁移、将 M2 样巨噬细胞重编程为 M1 表型和增强抗肿瘤免疫力来抑制结直肠癌的进展。更重要的是，化合物21作为单一药物，在体内抗结直肠癌疗效显着优于PLX3397，突出了结直肠癌免疫治疗的有希望的候选者。

  DOI：

  10.1021/acs.jmedchem.1c01184

文献信息

• USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS
  申请人：Webb Hsu Heather K.

  公开号：US20090270452A1

  公开（公告）日：2009-10-29

  Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome.

  本文揭示了一种通过给予可溶性环氧化物水解酶抑制剂来增强受试者平滑肌功能的化合物、组合物和方法，并用于治疗患有平滑肌障碍的受试者，包括勃起功能障碍、膀胱过度活跃、子宫收缩和肠易激综合征。
• 一种用于抗肿瘤的药物及其制备方法
  申请人：贵阳中医学院

  公开号：CN109134453A

  公开（公告）日：2019-01-04

  本发明涉及一种抗肿瘤的药物，所述药物为苯并三唑类化合物。本发明化合物对于人肝癌细胞株Hep G2、Hep 3B、人胃癌细胞株SGC‑7901、HS‑746T具有很好的增殖抑制作用，所述增殖抑制作用不劣于索拉非尼，部分化合物甚至具有远超过索拉非尼的抑制活性，因此可用于治疗各种癌症，特别是肝癌和胃癌。
• PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS
  申请人：Gless Richard D.

  公开号：US20080207908A1

  公开（公告）日：2008-08-28

  Disclosed are processes for the synthesis of piperidinyl-substituted urea compounds. This invention further relates to novel intermediates prepared during this synthesis.

  本发明涉及合成哌啶基取代的脲类化合物的过程。此外，本发明还涉及在该合成过程中制备的新型中间体。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS
  申请人：Hsu Heather Kay Webb

  公开号：US20080221105A1

  公开（公告）日：2008-09-11

  Compounds, compositions, and methods for inhibiting the onset of metabolic syndrome and treating related disorders in a subject in need of such therapy are disclosed.

  本发明揭示了用于抑制代谢综合征的发生和治疗相关疾病的化合物、组合物和方法，适用于需要此类治疗的受试者。
• Optimisation of ITK inhibitors through successive iterative design cycles
  作者：Matthias Herdemann、Alexander Weber、Jérôme Jonveaux、Frank Schwoebel、Michael Stoeck、Isabelle Heit

  DOI：10.1016/j.bmcl.2011.01.035

  日期：2011.3

  Based on a hit cluster of compounds inhibiting interleukin-2 inducible T-cell kinase (ITK) in the submicromolar range a series of ITK inhibitor libraries were synthesized. Through iterative design cycles including kinase crystal structure information, indolylindazole libraries were identified which showed low nanomolar activity in enzymatic and cellular assays. The potential of these novel lead series was confirmed through in vivo tests in an anti-CD3-IL2 mouse model. The intravenous administration of highly potent ITK inhibitor 11o resulted in dose-dependent, efficient suppression of IL-2. (C) 2011 Elsevier Ltd. All rights reserved.